After binding to the ligand, PROTACs enter the tumour cell, bind specifically to one end of the EZH2 protein, and recruit ubiquitin E3 ligase at the other end to form a triplet EZH2-PROTAC-E3 ligase complex [22]. Here, EZH2 is linked to neoplasm.